Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Agnosia 1

Interventions

Cyclophosphamide 19 Vincristine 14 Methotrexate 13 blinatumomab 12 Prednisone 12 Cytarabine 12 merphos 11 Specimen Handling 10 Mercaptopurine 10 prednylidene 9 pegaspargase 9 deltacortene 9 azathiopurine 9 N,N-dicyclohexyl-isoborneol-10-sulfonamide 9 Dexamethasone 9 Leucovorin 8 Doxorubicin 8 Biopsy 8 dexamethasone acetate 7 dexamethasone 21-phosphate 7 auricularum 7 Etoposide 7 Calcium Dobesilate 7 Thioguanine 6 Spinal Puncture 6 Daunorubicin 6 Asparaginase 6 venetoclax 5 fludarabine 5 calaspargase pegol 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × Acetaminophen × 30 days × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡